1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow SERD* + everolimus: new trials by email Literature Review of SERD* + everolimus trials Research Report on SERD* + everolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
UNC Lineberger Comprehensive Cancer Center (1)
United States (1)
Eric Winer, MD (1) · Lisa A Carey, MD (1)